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Abstract
Parkinson’s disease (PD) is a neurodegenerative disease that affects 1% of the popu-
lation aged 65 and over and is the second most common neurodegenerative disease 
next to Alzheimer’s disease. Interneuronal proteinaceous inclusions called Lewy bod-
ies (LB) and a selective degeneration of dopaminergic neurons of the substantia nigra 
pars compacta (SNPC) are the main features of PD pathology. The most common clinical 
manifestations are rigidity, tremor, bradykinesia, postural instability, sleep disorders, 
alterations in gait, smell, memory, and dementia. Genetic and environmental factors 
are involved in PD, and, recently, oxidative stress, proteasome-mediated protein deg-
radation, and inflammation have acquired relevance as major mechanisms of neuronal 
dysfunction. Increased levels of reactive oxygen and nitrogen species in the brain con-
tribute to greater vulnerability of proteins to nitro-oxidative modification and to greater 
degrees of aggregation. These protein aggregates contain a variety of proteins of which 
α-synuclein appears to be the main structural component. Interestingly, α-synuclein 
can be secreted by neuronal cells and may lead the initiation and the maintenance 
of inflammatory events through the activation of microglia, which contributes to dopa-
minergic neuron depletion. New evidence also suggests that PD may be the result 
of an  autoimmune response in which the immune cells recognize the neurons as foreign 
elements and would act against them, causing their death.
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1. Introduction
The central nervous system (CNS) has traditionally been considered immunologically privi-
leged due to the protection conferred by the blood-brain barrier; it lacks lymphatic vessels 
and is devoid of dendritic cells, and the parenchyma cells do not express major histocompati-
bility complex (MHC) class-I antigen-presenting molecules. However, the CNS can modulate 
the immune response and limit inflammation-induced tissue damage [1]. Neurons of the CNS 
are actively involved in control of the immune response by modulating the function of glial 
cells and T lymphocytes. There are mechanisms involved in the control of the immune 
response: the direct contact through membrane glycoproteins (CD22, CD47, CD200), neural 
cell adhesion molecules (NCAM or CD56), intercellular cell adhesion molecule-1 (ICAM-1), 
semaphorins and cadherins, and the mechanism independent of cell-cell contact that involves 
the expression of the Fas ligand or CD95L, which promote apoptosis of microglial cells and T 
lymphocytes. The immune system is not a completely autonomous system since the lymphoid 
organs are innervated by cholinergic, catecholaminergic, and peptidergic neurons and other 
neurons [2]. Thus, the nervous system and the immune system can interact not only through 
the hypothalamic-pituitary-adrenal axis, whose activation leads to the synthesis of cortico-
steroids that inhibit the immune response, but can also do so through neuronal circuits at 
the central level through the autonomic nervous system (ANS), both sympathetic and para-
sympathetic, which, through sensory and effector circuits, transmit impulses that reflexively 
induce the implementation of an anti-inflammatory response. In physiological conditions, 
the sensory and afferent fibers of the ANS travel in the vagus nerve from the peripheral 
tissues to the CNS to provide information about tissue function or, on the contrary, about 
the existence of injury within tissues that leads to the development of a cytokine-induced 
inflammatory process. The afferent sensory stimulus triggers a response in the CNS that 
includes the signs and symptoms of the disease and the efferent sympathetic pathway, called 
the cholinergic anti-inflammatory reflex, which, through the vagus nerve, inhibits the syn-
thesis of pro-inflammatory cytokines and thus limits or prevents tissue damage produced by 
these mediators.
Pro-inflammatory cytokines such as tumor necrosis factor (TNF), interleukin (IL)-1, and IL-6, 
produced during the activation of innate immunity cells in peripheral tissues, are able to mod-
ulate the activity of CNS neuronal circuits through specific receptors expressed by neurons 
of the hypothalamus and other regions of the brain. In this way, a response is characterized 
by the transmission of action potentials that trigger local and systemic symptoms and signs 
of the disease syndrome, which are then controlled by the cholinergic and anti-inflammatory 
vagal route. This CNS response leads not only to control the progression of the inflammatory pro-
cess in the peripheral tissue but also to prevent eventual immune-mediated tissue damage. Thus, 
the immunological activation of this neuronal circuit confers protection against tissue damage by 
inhibiting the release of cytokines during infection, autoimmunity, shock, and other inflamma-
tory syndromes in the CNS.
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